Stockreport

iBio Touts Bispecific Antibody Strategy for PH-HFpEF, Eyes Development Candidate in Q3 [Yahoo! Finance]

iBio, Inc.  (IBIO) 
NASDAQ:AMEX Investor Relations: ir.ibioinc.com
PDF associated with HFpEF ( PH-HFpEF ), and expects to declare a development candidate in Q3 while aiming for chronic subcutaneous dosing. Management ties the program to i [Read more]